{
    "clinical_study": {
        "@rank": "36740", 
        "acronym": "02", 
        "arm_group": [
            {
                "arm_group_label": "Aplisol", 
                "arm_group_type": "Experimental", 
                "description": "To compare new PPD to reference standard material"
            }, 
            {
                "arm_group_label": "Reference standard", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Response of standard material"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to determine bioequivalence of PPD material versus Reference Standard."
        }, 
        "brief_title": "Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard (PPD-S2)", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Tuberculosis Identification.", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "detailed_description": {
            "textblock": "This study is a multicenter, double-blind, active-controlled parallel-group study to\n      determine the bioequivalence of newly produced PPD material versus PPD-S2 in the detection\n      of male and female subjects with current or previously diagnosed intrathoracic Mtb\n      infection, as documented by a positive culture for Mtb (preferred method), by their primary\n      care or attending physician and/or by the subject's current or prior medical records (ie,\n      sensitivity determination)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males or nonpregnant females age 18 to 60 years\n\n          2. Documented PPD reactivity of 5 to 21 mm in the past, documented in a medical record.\n             Self-reported PPD reactivity will be acc\n\n          3. Give written informed consent to participate\n\n          4. Generally healthy, as determined by medical history and targeted physical\n             examination, if indicated\n\n          5. Possess 2 forearms that are free of burns, scars, eczema, or any physical deformity,\n             which could impair injection of study prepar\n\n          6. Comprehension of the study requirements; expressed availability for the required\n             study period, including readings at the nomina\n\n        Exclusion Criteria:\n\n          1. Prior PPD test within the past 30 days\n\n          2. Subject is of childbearing potential and unable to use contraceptives; is planning\n             pregnancy; is pregnant or lactating\n\n          3. History of anaphylactic reaction, severe positive tuberculin reaction (eg,\n             ulceration, necrosis) or other severe reaction to PPD in\n\n          4. Subject received a Bacillus Calmette-Gu\u00e9rin (BCG) vaccination in the past, or was\n             born or lived outside the US as a child and is\n\n          5. Presence of conditions that may suppress TST reactivity -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798121", 
            "org_study_id": "JHP-Aplisol-02"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Aplisol", 
                    "Reference standard"
                ], 
                "description": "Aplisol@ will be compared to reference standard material", 
                "intervention_name": "To compare new PPD to reference standard material", 
                "intervention_type": "Biological", 
                "other_name": "Aplisol@"
            }, 
            {
                "arm_group_label": "Aplisol", 
                "description": "Response of reference standard material compared to Aplisol@.", 
                "intervention_name": "Reference standard", 
                "intervention_type": "Biological", 
                "other_name": "Tuberculin PPD Standard."
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "PPD", 
            "Tuberculosis"
        ], 
        "lastchanged_date": "February 21, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard Tuberculin Purified Protein Derivative (PPD-S2) for Detection of Tuberculosis in Subjects With a Confirmed Diagnosis of Tuberculosis.", 
        "overall_contact": {
            "email": "arlene.lund@incresearch.com", 
            "last_name": "Arlene Lund, B.Sc.", 
            "phone": "919-985-3220"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine bio-equivalence of material used in trial by means of dose response and reaction sizes in patients.", 
            "measure": "Compare new PPD to Reference Standard", 
            "safety_issue": "No", 
            "time_frame": "72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798121"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "JHP Pharmaceuticals LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "INC Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "JHP Pharmaceuticals LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}